"Turkish Validation and Reliability Study of the Brompton Breathing Pattern Assessment Tool in Asthma Patients" (BPAT-Turkish)

May 2, 2026 updated by: Dilek Unsal, Istanbul Saglik Bilimleri University

Validity and Reliability Study of the Turkish Version of the Brompton Breathing Pattern Assessment Tool (BPAT) in Individuals With Asthma

The purpose of this study is to evaluate the validity and reliability of the Turkish version of the Brompton Breathing Pattern Assessment Tool (BPAT) in individuals with asthma. This study aims to determine whether the BPAT is a valid and reliable tool for assessing breathing patterns in Turkish-speaking asthma patients. The research question being addressed is: "Is the Turkish version of the BPAT a valid and reliable tool for assessing breathing patterns in individuals with asthma?"

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study is designed to assess the validity and reliability of the Turkish version of the Brompton Breathing Pattern Assessment Tool (BPAT). BPAT is a well-established tool used to assess the breathing patterns of individuals with respiratory conditions. In this study, a group of asthma patients will be evaluated using the BPAT to determine its applicability and consistency in the Turkish-speaking population.

The reliability of the tool will be tested through repeated measurements, and its validity will be assessed by comparing BPAT results with other validated asthma assessment tools. The data will be analyzed to evaluate the internal consistency, test-retest reliability, and construct validity of the BPAT in a clinical asthma population.

The linguistic validation process will be conducted following the ISPOR Task Force guidelines, including forward translation, reconciliation, back-translation, and cognitive debriefing. The psychometric properties of the tool, including internal consistency, test-retest reliability, and construct validity, will be evaluated according to the COSMIN checklist standards.

Additionally, participant eligibility will be defined as individuals who are diagnosed with asthma and can understand and respond to questions in Turkish. The study will also explore any cultural adaptations necessary for the Turkish version of the BPAT to ensure its cultural relevance and accuracy in assessments.

Study Type

Observational

Enrollment (Actual)

101

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Istanbul
      • Istanbul, Istanbul, Turkey (Türkiye), 34844
        • Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The participants for this study will be recruited from Health Sciences University, İstanbul Süreyyapaşa Chest Diseases and Chest Surgery Education and Research Hospital in Istanbul, Turkey. Participants will be selected based on the eligibility criteria outlined, including those diagnosed with severe persistent asthma as per the Global Initiative for Asthma (GINA) guidelines. Participants will be recruited from local clinics specializing in respiratory diseases and asthma management.

Description

Inclusion Criteria:

  • Aged between 18 and 75 years
  • Diagnosed with severe persistent asthma according to the Global Initiative for Asthma (GINA) criteria
  • Turkish ethnicity
  • Ability to read and write in Turkish
  • Willingness to participate in the study

Exclusion Criteria:

  • Having had a respiratory infection in the last 1 month
  • Use of oral corticosteroids in the last 4 weeks
  • Presence of malignancy, vasculitis, or pregnancy
  • Body Mass Index (BMI) > 35 kg/m2
  • Diagnosis of COPD or other primary respiratory diseases (excluding asthma)
  • Any musculoskeletal, neurological, or cardiovascular condition that could interfere with breathing pattern assessment or impede potential respiratory physiotherapy applications

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Asthma Patients
Individuals aged 18-75, diagnosed with severe persistent asthma according to GINA criteria, who are native Turkish speakers.
Other: Brompton Breathing Pattern Assessment Tool (BPAT) - Turkish Version
A tool used to assess breathing patterns in asthma patients through clinical observation.
Other: Validation Battery (Nijmegen Questionnaire, Dyspnea-12, Asthma Control Test (ACT), Asthma Quality of Life Questionnaire (Mini AQLQ), Spirometry)
A set of validated questionnaires and objective tests used to compare with BPAT results for construct validity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Construct Validity of the Turkish Version of the Brompton Breathing Pattern Assessment Tool (BPAT)
Time Frame: Baseline
The study aims to evaluate the construct validity of the Turkish version of the BPAT in assessing breathing patterns among Turkish-speaking asthma patients. Validity will be determined by calculating correlation coefficients (e.g., Spearman's or Pearson's r) between the total BPAT scores, objective physiological measures (spirometry results such as FEV1 and FVC), and the scores of established reference clinical tools (Nijmegen Questionnaire, Dyspnea-12, Asthma Control Test (ACT), and Asthma Quality of Life Questionnaire (Mini-AQLQ).
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Test-Retest Reliability of the Turkish Version of BPAT
Time Frame: 7 to 14 days
This outcome will assess the test-retest reliability of the Turkish version of BPAT by measuring the consistency of the tool in repeated assessments. The BPAT will be administered twice to the same participants. Reliability will be evaluated by calculating the Intraclass Correlation Coefficient (ICC).
7 to 14 days
Inter-Rater Reliability of the Turkish Version of BPAT
Time Frame: Baseline
This outcome will assess the inter-rater reliability of the Turkish version of BPAT. Two independent physiotherapists will evaluate the breathing pattern of the same asthma patient. The raters will be blinded to each other's scores to determine the consistency of the tool's application between different users. Reliability will be evaluated by calculating the Intraclass Correlation Coefficient (ICC) or Cohen's Kappa.
Baseline
Comparison of BPAT Results with Other Asthma Assessment Tools
Time Frame: Baseline
Description: This outcome will compare the BPAT results with other validated asthma assessment tools, such as Nijmegen Questionnaire, Dyspnea-12 Questionnaire , spirometry, ACT (Asthma Control Test), and Mini AQLQ (Asthma Quality of Life Questionnaire), to determine the congruence between different assessment methods.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul Saglik Bilimleri University

Collaborators

Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital

Investigators

  • Principal Investigator: Zuhal Kunduracılar, Prof., İstanbul Gelisim University
  • Study Chair: Fatma M. Tepetam, Prof., Saglik Bilimleri Universitesi
  • Study Chair: Şeyma Ozden, Dr., Saglik Bilimleri Universitesi
  • Principal Investigator: Dilek Unsal, PT PhD(c), Saglik Bilimleri Universitesi
  • Study Chair: Nisanur Tutus, PT Phd (c), Saglik Bilimleri Universitesi

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 14, 2025

Primary Completion (Actual)

April 30, 2026

Study Completion (Actual)

April 30, 2026

Study Registration Dates

First Submitted

September 28, 2025

First Submitted That Met QC Criteria

March 3, 2026

First Posted (Actual)

March 5, 2026

Study Record Updates

Last Update Posted (Actual)

May 7, 2026

Last Update Submitted That Met QC Criteria

May 2, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 25/428

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly shared in order to protect patient confidentiality and comply with the local ethics committee regulations. However, completely anonymized data may be made available upon reasonable academic request to the Principal Investigator following the publication of the study results.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Brompton Breathing Pattern Assessment Tool (BPAT) - Turkish Version

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe